Institute for Evidence-Based Healthcare, Bond University, Gold Coast, QLD.
Griffith University, Sunshine Coast, QLD.
Med J Aust. 2020 Mar;212(4):163-168. doi: 10.5694/mja2.50455. Epub 2019 Dec 19.
To estimate the proportion of cancer diagnoses in Australia that might reasonably be attributed to overdiagnosis by comparing current and past lifetime risks of cancer.
DESIGN, SETTING, AND PARTICIPANTS: Routinely collected Australian Institute of Health and Welfare national data were analysed to estimate recent (2012) and historical (1982) lifetime risks (adjusted for competing risk of death and changes in risk factors) of diagnoses with five cancers: prostate, breast, renal, thyroid cancers, and melanoma.
Difference in lifetime risks of cancer diagnosis between 1982 and 2012, interpreted as probable overdiagnosis.
For women, absolute lifetime risk increased by 3.4 percentage points for breast cancer (invasive cancers, 1.7 percentage points), 0.6 percentage point for renal cancer, 1.0 percentage point for thyroid cancer, and 5.1 percentage points for melanoma (invasive melanoma, 0.7 percentage point). An estimated 22% of breast cancers (invasive cancers, 13%), 58% of renal cancers, 73% of thyroid cancers, and 54% of melanomas (invasive melanoma, 15%) were overdiagnosed, or 18% of all cancer diagnoses (8% of invasive cancer diagnoses). For men, absolute lifetime risk increased by 8.2 percentage points for prostate cancer, 0.8 percentage point for renal cancer, 0.4 percentage point for thyroid cancer, and 8.0 percentage points for melanoma (invasive melanoma, 1.5 percentage points). An estimated 42% of prostate cancers, 42% of renal cancers, 73% of thyroid cancers, and 58% of melanomas (invasive melanomas, 22%) were overdiagnosed, or 24% of all cancer diagnoses (16% of invasive cancer diagnoses). Alternative assumptions slightly modified the estimates for overdiagnosis of breast cancer and melanoma.
About 11 000 cancers in women and 18 000 in men may be overdiagnosed each year. Rates of overdiagnosis need to be reduced and health services should monitor emerging areas of overdiagnosis.
通过比较当前和过去的癌症终生风险,来估计澳大利亚癌症诊断中可能归因于过度诊断的比例。
设计、设置和参与者:对澳大利亚卫生福利研究所的常规收集的全国数据进行分析,以估计最近(2012 年)和历史(1982 年)五种癌症的终生风险(调整了竞争死亡风险和危险因素的变化):前列腺癌、乳腺癌、肾癌、甲状腺癌和黑色素瘤。
1982 年至 2012 年期间癌症诊断的终生风险差异,解释为可能的过度诊断。
对于女性,乳腺癌(浸润性癌,1.7 个百分点)的绝对终生风险增加了 3.4 个百分点,肾癌增加了 0.6 个百分点,甲状腺癌增加了 1.0 个百分点,黑色素瘤(侵袭性黑色素瘤,0.7 个百分点)增加了 5.1 个百分点。估计有 22%的乳腺癌(浸润性癌,13%)、58%的肾癌、73%的甲状腺癌和 54%的黑色素瘤(侵袭性黑色素瘤,15%)是过度诊断的,或所有癌症诊断的 18%(8%的浸润性癌诊断)。对于男性,前列腺癌的绝对终生风险增加了 8.2 个百分点,肾癌增加了 0.8 个百分点,甲状腺癌增加了 0.4 个百分点,黑色素瘤(侵袭性黑色素瘤,1.5 个百分点)增加了 8.0 个百分点。估计有 42%的前列腺癌、42%的肾癌、73%的甲状腺癌和 58%的黑色素瘤(侵袭性黑色素瘤,22%)是过度诊断的,或所有癌症诊断的 24%(16%的浸润性癌诊断)。替代假设略微修改了乳腺癌和黑色素瘤过度诊断的估计。
每年可能有 11000 例女性癌症和 18000 例男性癌症被过度诊断。需要降低过度诊断率,卫生服务机构应监测新出现的过度诊断领域。